Event Type
Disclosure
Voluntary
Variant
8-K
Regulation FD Disclosure. On February 11, 2026, the Company issued a press release announcing that that the U.S. Food and Drug Administration (FDA) has approved
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of NovoCure Limited, dated February 11, 2026 104 Cover Page Interactiv